---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-293899"
form_type: "8-K"
ticker: "TYRA"
cik: "0001863127"
company_name: "Tyra Biosciences, Inc."
filed_at: "2022-11-29T23:59:59+00:00"
generated_at: "2026-06-21T12:26:57.966047+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tyra Biosciences doses first patient in Phase 1/2 SURF301 study of TYRA-300

## Summary
- First patient dosed in SURF301 Phase 1/2 study of TYRA-300 for FGFR3+ advanced solid tumors.
- Multi-center, open-label study to determine optimal/MTD/RP2D and evaluate antitumor activity.
- Study targets both untreated and resistant FGFR3+ solid tumors; announced Nov 29, 2022.

## SEC filing metadata
- accession: 0001193125-22-293899
- form_type: 8-K
- ticker: TYRA
- cik: 0001863127
- company_name: Tyra Biosciences, Inc.
- filed_at: 2022-11-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1863127/000119312522293899/0001193125-22-293899-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1863127/000119312522293899/d423130d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-293899
- JSON: https://secwatch.observer/filing/0001193125-22-293899.json
- Plain text: https://secwatch.observer/filing/0001193125-22-293899.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.